A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
A Comparative Study of Montelukast and Azelastine add on Therapy in Moderate to Severe Allergic Rhinitis Treatment: A Double-Blind Randomized Clinical Trial
CONCLUSION: Based on our findings, we recommend Azelastine in conjunction with an intranasal corticosteroid for the treatment of moderate to severe allergic rhinitis. In moderate to severe AR or even asthma management, Montelukast has no greater impact than INCS.PMID:35300506 | DOI:10.1177/19458924221086268 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - March 18, 2022 Category: ENT & OMF Authors: Hossein Esmaeilzadeh Nasrin Mortazavi Far Seyed Hesamedin Nabavizadeh Masroor Babaeian Maryam Hadipour Soheila Alyasin Source Type: research
Trends in Nasal Spray Prescribing Patterns by Otolaryngologists in the US Medicare Population
CONCLUSIONS: Otolaryngologists are prescribing azelastine HCl and ipratropium at an increasingly higher rate in the Medicare population, while the rate for fluticasone propionate has been decreasing nationally. Utilization and costs of nasal sprays also vary geographically across the United States.PMID:34823366 | DOI:10.1177/00034894211060902 (Source: The Annals of Otology, Rhinology, and Laryngology)
Source: The Annals of Otology, Rhinology, and Laryngology - November 26, 2021 Category: ENT & OMF Authors: Celeste Kim Erica Tran Ian Kim Kevin Hur Source Type: research
Trends in Nasal Spray Prescribing Patterns by Otolaryngologists in the US Medicare Population
CONCLUSIONS: Otolaryngologists are prescribing azelastine HCl and ipratropium at an increasingly higher rate in the Medicare population, while the rate for fluticasone propionate has been decreasing nationally. Utilization and costs of nasal sprays also vary geographically across the United States.PMID:34823366 | DOI:10.1177/00034894211060902 (Source: The Annals of Otology, Rhinology, and Laryngology)
Source: The Annals of Otology, Rhinology, and Laryngology - November 26, 2021 Category: ENT & OMF Authors: Celeste Kim Erica Tran Ian Kim Kevin Hur Source Type: research
Trends in Nasal Spray Prescribing Patterns by Otolaryngologists in the US Medicare Population
CONCLUSIONS: Otolaryngologists are prescribing azelastine HCl and ipratropium at an increasingly higher rate in the Medicare population, while the rate for fluticasone propionate has been decreasing nationally. Utilization and costs of nasal sprays also vary geographically across the United States.PMID:34823366 | DOI:10.1177/00034894211060902 (Source: The Annals of Otology, Rhinology, and Laryngology)
Source: The Annals of Otology, Rhinology, and Laryngology - November 26, 2021 Category: ENT & OMF Authors: Celeste Kim Erica Tran Ian Kim Kevin Hur Source Type: research
Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy
ConclusionAZE/FP, FP, and AZE had diverse effects on immune gene expression profiles in nasal mucosa samples. The moderate number of genes modulated by AZE/FP indicates alternative pathways in reducing AR symptoms whilst avoiding extensive local immune suppression. (Source: Immunity, Inflammation and Disease)
Source: Immunity, Inflammation and Disease - November 23, 2021 Category: Allergy & Immunology Authors: Annabelle M. Watts,
Nicholas P. West,
Peter K. Smith,
Ping Zhang,
Allan W. Cripps,
Amanda J. Cox Tags: ORIGINAL ARTICLE Source Type: research
Use of Azelastine and Sodium Chloride Spray for Prevention of Sinusitis in ICU Admitted Patients: A Randomized Clinical Trial
Conclusions: The findings of the present study offer an inexpensive, low ‑risk, and efficacious intervention for the prevention of upper respiratory tract infections in ICU patients. (Source: International Journal of Preventive Medicine)
Source: International Journal of Preventive Medicine - October 18, 2021 Category: International Medicine & Public Health Source Type: research
Effect of azelastine hydrochloride combined with montelukast sodium in the treatment of patients with allergic rhinitis
CONCLUSION: Azelastine hydrochloride combined with montelukast sodium can effectively improve clinical symptoms and inflammatory reactions in patients with allergic rhinitis; furthermore, this research provides ideas for clinical practice.PMID:34540080 | PMC:PMC8430178 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - September 20, 2021 Category: Research Authors: Qiling Zheng Dijiang Ma Qi Zhu Shenjun Tang Chengbo Chen Source Type: research
